Marketresearchnews

Monday, 10 May 2021

Nuclear Medicine Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Market Research Future (MRFR)’s report highlights that the global nuclear medicine market size is likely to strike a CAGR of 6.2% during the forecast period 2018 to 2023. The valuation of the market is expected to witness a growth of USD 5.430 Bn by the end of 2023. The growth of the market is dictated by increasing incidences of target conditions such as Cardiovascular Diseases (CVD) and cancer. Furthermore, the exponentially growing geriatric population is poised to add to the patient pool. The rising inclination towards the use of radiopharmaceuticals for the treatment of geriatric population is prognosticated to generate significant demand for nuclear medicines in the foreseeable future.

The market looks lucrative and is expanding at a significant pace. It is anticipated to witness constant growth over the next couple of years owing to increasing applications, discoveries, etc. Nevertheless, the expensiveness of the radiopharmaceuticals and side effects related to radiation exposure remain impediments to the market proliferation.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6674

Report Coverage:

The report covers an in-depth study of the historical trends, current market status, forecast, and key players’ market share analysis. It also encompasses market factor analysis which includes supply chain analysis and Porter’s five forces analysis. The market is analyzed in detail by region as well as segmentation, and, a country-level analysis for each segment is also available in the report.

Report Overview:

This MRFR’s report offers a detailed five-year forecast (2018 to 2023) for the global nuclear medicine market. It reflects a revenue analysis of the different product types, including diagnostic nuclear medicine and therapeutic radiopharmaceuticals. The major applications discussed in the study encompasses diagnostic applications and therapeutic applications. The report also presents a detailed analysis of the end-users such as hospitals & diagnostic centers, research institutes, and others. A regional assessment of the market is published in the report for enhanced lucidity, which covers Americas, Europe, Asia Pacific, and the Middle East & Africa.

Companies Covered:

Some of the key players operating in the market are Cardinal Health, GE Healthcare, Bayer, Bracco Imaging, Curium, Lantheus Medical Imaging, Nordion Inc., Advanced Accelerators Applications, Mallinckrodt Pharmaceuticals, Jubliant Lifesciences, and Medtronic plc.

Research Methodology:

MRFR strives to leverage its industry expertise for offering insightful conclusions into the market that reflects the latest trends and foresight. Analytical algorithms are utilized for assessing and challenging the data curated through extensive primary and secondary research. The credible sources referred for data collection include interviews, SEC filings, whitepaper references, paid database services, etc. A multi-layer verification process authenticates the premium quality and reliability of the statistical observations offered in the report. Additionally, top-down and bottom-up approaches are employed for re-validating the accuracy of the quantitative assessment of the market.

Market Segmentation

MRFR has conducted a detailed study of the various parts of the nuclear medicine market which has been segmented on the basis of product type, application, end-user, and region. By product types, the nuclear medicine market has been segmented into diagnostic nuclear medicine and therapeutic radiopharmaceuticals. At present, the diagnostic nuclear medicine segment has attained a leadership position. However, the therapeutic radiopharmaceuticals segment is the fastest growing segment during the forecast period. The diagnostic nuclear medicine segment is segmented further into SPECT radiopharmaceuticals, and PET radiopharmaceuticals. Meanwhile, the therapeutic radiopharmaceuticals segment is sub-segmented into alpha emitters, beta emitters, and brachytherapy isotopes.

Applications of nuclear medicine are segmented into diagnostic applications and therapeutic applications. Diagnostic applications is a major segment which is sub-segmented into SPECT applications and PET applications. Meanwhile, the therapeutic applications segment is growing at the fastest pace.

End-users have been segmented into hospitals & diagnostic centers, research institutes, and others. Research institutes display the highest potential for growth over the forecast period, while hospitals & diagnostics centers have been identified as the most significant segment in terms of market share.

All sub-segments have been segmented further and included in the report.

Regional Analysis

The Americas due to the presence of North America has established itself as a market leader. The presence of several important market players combined with the high prevalence of cancer and other chronic diseases has influenced the growth of the Americas nuclear market. The region, particularly countries such as U.S & Canada have well-developed healthcare sectors which receive high investments. Moreover, the region has a high geriatric patient population which is expanding rapidly and is growing increasingly aware regarding advanced therapies.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nuclear-medicine-market-6674

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Magnetic Resonance Imaging (MRI) Systems Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Market Scenario

The global Magnetic Resonance Imaging (MRI) Systems market is expected to be of value USD 5 Billion in 2023 and to grow at a depict 3.5% CAGR during the forecast period. Magnetic resonance imaging (MRI) systems is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. Magnetic resonance imaging (MRI) systems are surpassing the radiology imaging market due to its myriad advantages over it. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of magnetic resonance imaging (MRI) systems techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market. However, the market growth is restricted by factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for magnetic resonance imaging (MRI) systems procedures.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6194

Market Segmentation

The global magnetic resonance imaging (MRI) systems market is segmented on the basis of type, field strength, disease application and end user.

Considering the type, the market is segmented into open MRI, closed MRI, standard bore MRI, wide-bore MRI.

On the basis of field strength, the market is segmented into high-field MRI systems, 1.5t MRI systems, 3t MRI systems, low-to-mid-field MRI systems, very-high-field MRI systems, and others.

On account of disease application, the market is segmented into the spine and musculoskeletal MRI, brain and neurological MRI, pelvic and abdominal MRI, breast MRI, cardiovascular MRI, and others

According to the end user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies.

Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

Market Players

Hitachi
Siemens AG
Canon Medical Systems
GE Healthcare
Philips
Toshiba Corporation
Toshiba Corporation
Xingaoyi
Aurora Imaging Technologies, Inc.

Regional Market Summary

In terms of geography, Americas dominates the market for Magnetic Resonance Imaging (MRI) systems owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders pertaining to rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in the medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems, and the presence of pharmaceutical giants also propel the market growth in this region. For instance, according to National Center for Health Statistics report in 2016, around 140,323 mortality occurred due to cerebrovascular disease or stroke in the US Thus, this rising patient pool is going to boost up the market growth during the forecast period.

Europe accounts for the second largest market and holds a healthy share in the global magnetic resonance Imaging (MRI) systems market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of Magnetic Resonance Imaging (MRI) Systems over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.

Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the Department of Neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period. Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in Magnetic Resonance Imaging (MRI) Systems market in future.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers. Hence, the market might show steady growth due to Saudi Arabia, the UAE market growth, and government initiatives to improve quality of healthcare in the Africa region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/magnetic-resonance-imaging-market-6194

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Neurocutaneous Disorder Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Market Scenario

The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord.

These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late. These syndromes cannot be cured, but various treatments can assist to manage the symptoms and any health concern. Lately, significant advances have been made by the use of DNA testing to confirm these syndromes in some people.

Global Neurocutaneous disorders market is expected to have a CAGR of approximately 6.5% during 2017 to 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5937

The three most common types of neurocutaneous syndromes are Tuberous sclerosis (TS), Neurofibromatosis (NF): Type I, Type II, and schwannomatosis, and Sturge-Weber disease.

Tuberous sclerosis (TS) is a non-cancerous growth that occurs in organs such as brain, eyes, kidneys, heart, lungs, bones, and skin. There is a 50% chance of children to develop TS if the parent is affected by it. Moreover, the Sturge-Weber Syndrome (SWS) causes malformations relating to the face, eye, and brain. It is estimated that about 1 in 20,000 to 50,000 live births may be affected with the Sturge-Weber syndrome.

Increasing government initiatives for ensuring the early diagnosis is supposed to be a significant driver of the market. Moreover, many guidelines are issued by government organizations to promote awareness related to effective prevention measures, globally. All these factors are expected to contribute to the market growth throughout the forecast period. Moreover, concerns regarding the safety of reprocessed instruments and stringent regulations for sterilization equipment manufacturers and service providers are factors hampering the market growth.

Segmentation

The global neurocutaneous disorder market has been segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the global neurocutaneous disorder market can be segmented into Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-weber syndrome, Ataxia-Telangiectasia (A-T), Von Hippel-Lindau disease (VHL), and others.

Neurofibromatosis (NF) is further divided into Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and schwannomatosis. The Sturge-weber syndrome is divided into type-1, type-2, and type-3.

On the basis of diagnosis, the global neurocutaneous disorder market can be segmented into skull radiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Electroencephalogram (EEG), genetic tests (blood testing), biopsy, and others

On the basis of treatment, the global neurocutaneous disorder market can be segmented into medication, laser therapy, surgical procedures, and others.

Medication is further divided into antiepileptic, beta-antagonist eye drops, carbonic anhydrase inhibitors, adrenergic eye drops, miotic eye drops, and others. Surgical procedures are further divided into focal cortical resection, hemispherectomy, corpus callosotomy, trabeculectomy, filtration surgery, cyclocryotherapy, Vagal Nerve Stimulation (VNS), and others.

On the basis of end-user, the global neurocutaneous disorder market is segmented into hospitals and clinics, diagnostic centers, and others.

Regional Analysis

The global neurocutaneous disorder market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region accounted for the largest market share of the global neurocutaneous disorder market owing to the increasing awareness about genetic disorders along with the growing number of drug and medical service providers. As per the National Institute of Neurological Disorders and Stroke (NINDS) in 2017, Neurofibromatosis Type 1 (NF1) occurs in about 1 in 3,000 to 4,000 births in the U.S. This condition is a chromosomal disorder which is inherited from a parent. Moreover, Neurofibromatosis Type 2 (NF2) occurs less frequently, affecting about 1 in 25,000 births in the U.S.

The European neurocutaneous disorder market is the second largest market followed by Asia Pacific. The Asia Pacific region is expected to exhibit the fastest growth throughout the forecast period owing to the exceptional healthcare standards and infrastructure, rising healthcare expenditure, and growing presence of outsourcing organizations across this region. Moreover, the presence of various government organizations dedicated to improving the standards for neurocutaneous disorders is among the significant factors contributing towards the growth of the Asia Pacific region.

The Middle Eastern region is expected to grow at a steady pace owing to factors such as the extensive development of the healthcare infrastructure and increasing R&D activities in the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/neurocutaneous-disorder-market-5937

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Obesity Treatment Market to Witness Widespread Expansion During 2020-2027

Market Scenario

Obesity is a disorder characterized by an excessive amount of body fat. The medical condition not only generates cosmetic concerns but is also related to various diseases and health problems, including heart diseases, diabetes, and others. A variety of treatment options are available in the market for obesity treatment, which ranges from medications to surgeries. Growing obese population and increasing acceptance of bariatric surgeries are expected to be the major drivers for the market growth during the forecast period. The Monash University stated that Australia recorded a burgeoning number of bariatric surgeries in 2015, accounting for approximately 15,000 procedures within the region. Moreover, the increasing demand for minimally invasive surgeries, rising awareness, and favorable reimbursement policies are expected to boost the market growth during the forecast period. However, factors such as high cost of surgery followed by the risks of infection and anesthesia allergy and low healthcare expenditure in the middle and low-income countries are estimated to restrain the market growth during the forecast period. According to a study published in the Obesity Surgery Journal in 2017, the mean total cost for bariatric procedures such as gastric bypass or adjustable gastric banding was estimated to be around USD 14,389.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5872

The Global Obesity Treatment Market is expected to grow at an approximate CAGR of 16.7% during forecast period.

Segmentation

The global obesity treatment market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into inactivity obesity, food obesity, anxiety obesity, venous obesity, atherogenic obesity, and gluten obesity. On the basis of diagnosis, the market is categorized into blood tests, physical examination, and others. The blood tests segment is sub-segmented into cholesterol test, liver function test, thyroid test, and others. The physical examination segment is sub-segmented into heart rate measurement, blood pressure measurement, and others. On the basis of treatment, the market is segmented into medication, surgery, lifestyle changes, and others. The medication segment is sub-segmented into orlistat, lorcaserin, phentermine and topiramate, liraglutide, and others. The surgery segment is sub-segmented into gastric bypass surgery, Laparoscopic Adjustable Gastric Banding (LAGB), gastric sleeve, biliopancreatic diversion, gastric sleeve, and others. On the basis of end-user, the market is segmented into hospitals, clinics, pharmacies, and others.

Key players

Some of the key players for the global obesity treatment market are VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), and others.

Regional Analysis

The Americas dominates the global market for obesity treatment due to an increasing obese population and presence of a well-developed healthcare sector. Moreover, factors such as changing lifestyle, the presence of developed economies, and increasing healthcare expenditure boost the market within the Americas.

Europe follows the Americas and stands second in the global obesity treatment market. The availability of funds for research, growing obese population, and increasing adoption of bariatric surgeries within the region are estimated to drive the market within the region. As per the Eurostat in 2016, more than half of the adults, accounting for 51.6% of the total population living within the European Union were estimated to be overweight. On a regional basis, Europe is divided into Western Europe and Eastern Europe. Western Europe leads the market in developed economies such as Italy, the U.K., France, and others.

Asia Pacific is estimated to be the fastest growing region and provides huge opportunities for the market growth. This can be attributed to the increasing obese population, continuously developing economies, and a growing healthcare sector within the region. From 2014–2015, the Australian Institute of Health and Welfare stated that approximately two-thirds, i.e., 63% of the Australian population, aged 18 or more, were estimated to be overweight or obese.

On the other hand, the Middle East and Africa holds the least share in the global obesity treatment market due to the presence of poor economies and stringent government policies, especially within the Africa region. A majority of the market of the Middle East and Africa is estimated to be held by the Middle East.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/obesity-treatment-market-5872

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Cervical Cancer Treatment Market Foraying into Emerging Economies 2020-2027

Market Synopsis

The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer develops in the cells of the cervix. Strains of Human Papillomavirus (HPV), a sexually transmitted infection, play a role in causing most of the cervical cancers. The disease begins when healthy cells acquire mutation leading to the uncontrolled growth of cells. These cells form a tumor which invades the nearby tissues. Squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas are three types of cervical cancers. Squamous cell carcinomas develop from cells in the exocervix while adenocarcinomas develop from gland cells. The cancer cells are said to have features of squamous cells under the microscope. Adenosquamous carcinomas feature both squamous cell carcinomas and adenocarcinomas. Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are various treatment options for cervical cancer. Cystoscopy, proctoscopy, examination under anesthesia, and imaging studies such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), intravenous urography, and Positron Emission Tomography (PET scan) are used of the diagnosis of cervical cancer.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5834

The cervical cancer treatment market is mainly driven by the increasing prevalence of cervical cancer and increasing awareness about cervical cancer among women. Furthermore, the increasing demand for early diagnosis and treatment of cervical cancer is also expected to fuel the growth of the market during the review period. However, the high cost of treatment also fuels the growth of the market. The World Health Organization (WHO) stated that cancer was the leading cause of the total number of deaths globally in 2015 and was responsible for 8.8 million deaths.

Global Cervical Cancer Treatment market is expected to grow at a CAGR of 6.5% during the forecast period.

Segments

The global cervical cancer treatment market is segmented on the basis of type, treatment, and end-user.

On the basis of type, the market is segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.

On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others.

Surgery is further segmented into cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others.

Radiation Therapy is further segmented into external beam radiation and brachytherapy

Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others.

Targeted therapy is further segmented into bevacizumab and pazopanib.

Hormone therapy is further segmented into oestrogen, progesterone, progestogens, and testosterone.

On the basis of end-user, the market is segmented into cancer care centers, diagnostic centers, pharmacies, and others.

Regional Analysis of the Global Cervical Cancer Treatment Market

Globally, Americas is the largest market for cervical cancer treatment whose growth is attributed to technological advancements in the field of oncology, increasing prevalence of cervical cancer, and development of new imaging devices by key players in the market. In North America, the market is driven by the increasing awareness of causes and risk factors of cervical cancer and its treatment. In the U.S., the market is driven by the increasing importance of women healthcare and changing lifestyle of women. South America exhibits a steady growth in the cervical cancer treatment market.

In the European countries, the growth of the market is attributed to a number of healthcare institutions offering treatment of cancer and huge investments in research and development activities by the U.K. and Germany. In Germany, the market is mainly driven by an increase in the use of new technological devices for the diagnosis and treatment of cancer.

In Asia Pacific, the cervical cancer treatment market exhibits numerous growth opportunities due to rising awareness about cervical cancer and the increasing demand for cost-effective treatment solutions such as chemotherapy. Japan, China, and India are the largest contributors to the market growth where the market is driven by the increasing emphasis on cancer detection and treatment and the rising prevalence of cancer. Additionally, availability of skilled healthcare professionals in research also accelerates the growth of the market. The increasing government support of oncology research and women healthcare initiatives and the rapid growth of the healthcare imaging industry in India and China fuel the f=growth of the market in the regions.

In the Middle East, Saudi Arabia and the United Arab Emirates (U.A.E.) are the largest contributors to the market growth due to the focus on the development of new healthcare facilities catering to the needs of cancer patients and availability of technologically advanced diagnostic devices of management. In African countries, the increasing number of healthcare initiatives for women health and improvement in healthcare infrastructure are likely to boost the growth of the market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cervical-cancer-treatment-market-5834

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Bone Metastasis Market to Witness Widespread Expansion During 2020-2027

Market Scenario

Bone metastasis is characterized by the spreading of cancerous cells from their original site to a bone. All types of cancer can show bone-metastasis. However, it is estimated that breast cancer and prostate cancer are commonly associated with the disease. The medical condition is frequent for spine, pelvis, and thighs. Urinary incontinence, bowel incontinence, and hypercalcemia are some of the common symptoms of the disease. The increasing prevalence of bone metastasis is expected to be a major driver for the market growth during the forecast period. According to a study published in the Oncology Reviews Journal in 2017, the relative occurrence of bone metastasis was estimated to be around 65 to 75% for both breast and prostate cancers suffering patients, respectively. Moreover, the growing geriatric population, increasing healthcare expenditures, and increasing R&D in the market are estimated to drive the market growth during the forecast period. According to the American Society of Clinical Oncology in 2016, approximately 60% of the total cancer patients aged 65 years or more. However, factors such as lack of healthcare services in low-income countries, the high cost of treatment, and related side effects are estimated to restrain the market growth during the forecast period. According to a study published in the Journal of Spine Surgery in 2017, the mean total cost of therapeutic modalities such as vertebroplasty was estimated to be about USD 14,114 in 2014.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5776

The global bone metastasis market is expected to grow at an approximate CAGR of 8.4% during the forecast period

Intended Audience

Pharmaceutical Companies
Biotechnological Institutes
Government and Private Laboratories
Research and Development (R&D) Companies
Medical Research Laboratories
Market Research and Consulting Service Providers

Segmentation

The global bone metastasis market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.

On the basis of diagnosis, the market is categorized into biopsy, blood test, imaging, and others. The imaging segment is sub-segmented into X-ray, bone scintigraphy, computerized tomography, magnetic resonance imaging, positron emission tomography, and others.

On the basis of the treatment, the market is segmented into medical therapies, surgery, medication, and others. The medical therapies segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others. The ablation therapy segment is further segmented into radiofrequency ablation, cryoablation, and others. The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and others. The medication segment is sub-segmented into pain medications, bone building medications, and others. The pain medication segment is sub-segmented into ibuprofen, morphine, and others. The bone-building medications segment is sub-segmented into corticosteroids, bisphosphonates, and others. The bisphosphonates segment is further segmented into teriparatide, pamidronate, medronate, and others.

On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, pharmacies, and ambulatory surgical centers.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bone-metastasis-market-5776

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Sunday, 9 May 2021

Substance Abuse Treatment Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

Market Scenario

Global substance abuse treatment market size is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 11.6% over the forecast period.

Substance abuse refers to the harmful use of psychoactive substances, including alcohol and illicit drugs.

Increasing trends of cigarette smoking in teenagers is one of the prominent factors driving the Substance Abuse Treatment market. According to the 2015 study published in the Clinical and Translational Investigation journal, More than 60% of individuals start smoking at the age of 13 and more than 90% individuals start smoking before reaching 20 years. It is also reported that 5.8% of the Mexican population comprises adolescents between 13 and 15 years. Of them, 42.8% tried a cigarette at some point in their life.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7230

Various other factors such as increasing incidence of drug addiction, technological advancement in the diagnostics industry, rising patient awareness about substance abuse treatment and improvement in treatment rates and healthcare infrastructure are also expected to propel the growth of the market.

However, poor treatment compliance in some countries and reluctance of individuals for accessing treatment can hamper the market growth over the forecast period.

Segmentation

The global substance abuse treatment market is segmented based on abuse type, treatment type, end user, and region.

The global market for substance abuse treatment, by abuse type is segmented into alcohol dependence, tobacco/nicotine addiction, and drug abuse. The drug abuse segment is anticipated to hold the largest market share owing to the increasing addiction of opioid.

The market, by treatment type, is segmented into alcohol addiction treatment, tobacco/nicotine addiction treatment, and drug abuse treatment. The alcohol addiction treatment segment is further classified as disulfiram, acamprosate, and naltrexone. The tobacco/nicotine addiction treatment segment is further classified as nicotine replacement treatment, and non-nicotine medication. The nicotine replacement treatment segment includes nicotine patch, nicotine gum, nicotine lozenge, nicotine spray, and nicotine inhaler. The non-nicotine medication segment includes bupropion, and varenicline. The drug abuse treatment segment is further classified as methadone, buprenorphine, and naltrexone.

Based on end user, the market is segmented into outpatient treatment centres, residential treatment centres, and inpatient treatment centres.

In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.

The substance abuse treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European substance abuse treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The substance abuse treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The substance abuse treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/substance-abuse-treatment-market-7230

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com